How to manage patients without signs or symptoms of gastroesophageal reflux disease (GERD) and with diagnosed Barret esophagus (without dysplasia)? Should proton pump inhibitors (PPIs) be used long term? At what dose? With Dr Paul Moayyedi.
Should prokinetic agents be used in GERD? If so, in all or selected patients? With Dr Paul Moayyedi.
Is there any association between Helicobacter pylori infection and gastroesophageal reflux disease (GERD)? Should patients be tested for Helicobacter pylori infection and receive eradication treatment (if the results are positive) before initiating proton pump inhibitors (PPIs)? With Dr Paul Moayyedi.
What are the principles of managing gastroesophageal reflux disease (GERD) in patients with obesity? With Dr Paul Moayyedi.
How to monitor the effectiveness of oral pancreatic enzyme supplementation in patients with chronic pancreatitis? When to increase the dose? Can pancreatic enzymes be overdosed? If yes, what are the signs and symptoms? Does the overdosing pose a risk to the patient? With Dr Marianna Arvanitakis.
What is the role of cannabinoids in inflammatory bowel disease (IBD) management?
Is there any diet that reduces or sustains the remission of inflammatory bowel disease (IBD) in adult patients?
What management do you recommend if specific biologic therapy is not effective for inflammatory bowel disease (IBD)? Should a biologic drug be replaced with another biologic agent with a different mechanism of action or should a Janus kinase (JAK) inhibitor be added? Is combined treatment with a biologic agent and a JAK inhibitor safe/possible?
What are the essential elements of acute liver failure management? Which elements of management are the most important for prognosis?
What are the adverse effects of JAK inhibitors (used in IBD treatment)? How should we monitor patients treated with JAK inhibitors? Which tests should be performed?
English
Polski
Español
українська